A Meta-Analysis to Determine the Effect of Pulmonary Hypertension on Patients With Systemic Sclerosis
Keywords:
SSc, DLCO, PH, Patients, Systemic sclerosisAbstract
A meta-analysis of six studies was conducted to evaluate potential variables associated with arterial hypertension in systemic sclerosis. The variables were classified into four categories: clinical and demographic parameters, laboratory tests, electrocardiogram, and echocardiogram. All patients were entitled to retrieve the previously described information if they were practicing cardiac care. The meta-analysis was conducted in three stages, selecting candidate variables associated with arterial hypertension.
The most serious complication of systemic sclerosis, a rare, progressive autoimmune disease that causes vascular dysfunction, fibrosis, and multi-organ involvement, is pulmonary hypertension, which leads to an increase in morbidity and mortality. The present case-control meta-analysis aims to evaluate the impact of pulmonary hypertension on clinical outcomes, such as survival rates, associated function decline, and risk factors, among patients with systemic sclerosis.
Meta-analysis shows that PH among SSc patients is associated with Increased Mortality where The pooled OR showed significantly increased risk for death among SSc-PH patients in comparison to the SSc non-PH cohorts (median survival post-diagnosis: 3-5 years) and Decline in Function Reduced 6MWD and advanced NYHA class (III/IV) were constantly reported, indicating severe impairments in exercise capacity and quality of life addition to assessment Risk Factors Impaired DLCO (<60%) and certain autoantibodies (anti-centromere, anti-Scl-70) are found to be good predictive markers for development of PH.
References
Denton C.P., Khanna D. Systemic sclerosis. Lancet. 2017;390:1685–1699. doi: 10.1016/S0140-6736(17)30933-9. [DOI] [PubMed] [Google Scholar]
Jimenez S.A., Derk C.T. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann. Intern Med. 2004;140:37–50. doi: 10.7326/0003-4819-140-1-200401060-00010. [DOI] [PubMed] [Google Scholar]
Allanore Y., Simms R., Distler O., Trojanowska M., Pope J., Denton C.P., Varga J. Systemic sclerosis. Nat. Rev. Dis. Prim. 2015;1:15002. doi: 10.1038/nrdp.2015.2. [DOI] [PubMed] [Google Scholar]
Simonneau G., Montani D., Celermajer D.S., Denton C.P., Gatzoulis M.A., Krowka M., Williams P.G., Souza R. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 2019;53:1801913. Doi: 10.1183/13993003.01913-2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
Clements P.J., Tan M., McLaughlin V.V., Oudiz R.J., Tapson V.F., Channick R.N., Rubin L.J., Langer A. Pulmonary Arterial Hyper-tension Quality Enhancement Research Initiative, I. The pulmonary arterial hypertension quality enhancement research initiative: Comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. Ann. Rheum. Dis. 2012;71:249–252. doi: 10.1136/annrheumdis-2011-200265. [DOI] [PubMed] [Google Scholar]
Fisher M.R., Mathai S.C., Champion H.C., Girgis R.E., Housten-Harris T., Hummers L., Krishnan J.A., Wigley F., Hassoun P.M. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006;54:3043–3050. doi: 10.1002/art.22069. [DOI] [PubMed] [Google Scholar]
Avouac J., Airo P., Meune C., Beretta L., Dieude P., Caramaschi P., Tiev K., Cappelli S., Diot E., Vacca A., et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies. J. Rheumatol. 2010;37:2290–2298. doi: 10.3899/jrheum.100245. [DOI] [PubMed] [Google Scholar]
Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann. Intern. Med. 2004;140 (1):37–50. [PubMed] [Google Scholar]
Tan FK. Systemic sclerosis: the susceptible host (genetics and environment). Rheum. Dis. Clin. North Am. 2003;29 (2):211–237. doi: 10.1016/s0889-857x (03)00015-2. [DOI] [PubMed] [Google Scholar]
Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 2001;44 (6):1359–1362. doi: 10.1002/1529-0131 (200106)44:6<1359::AID-ART228>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
Feghali-Bostwick C, Medsger TA, Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 2003;48 (7):1956–1963. doi: 10.1002/art.11173. [DOI] [PubMed] [Google Scholar]
Nietert PJ, Silver RM. Systemic sclerosis: environmental and occupational risk factors. Curr. Opin. Rheumatol. 2000;12 (6):520–526. doi: 10.1097/00002281-200011000-00008. [DOI] [PubMed] [Google Scholar]
Mayes MD. Scleroderma epidemiology. Rheum. Dis. Clin. North Am. 2003;29 (2):239–254. doi: 10.1016/s0889-857x (03)00022-x. [DOI] [PubMed] [Google Scholar]
Mayes MD, Lacey JV, Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48 (8):2246–2255. doi: 10.1002/art.11073. [DOI] [PubMed] [Google Scholar]
Wigley FM. Vascular disease in scleroderma. Clin Rev Allergy Immunol. 2009;36:150–175. doi: 10.1007/s12016-008-8106-x. This article provides a useful review of the causes and consequences of scleroderma-associated vascular disease by a leader in the field. [DOI] [PubMed] [Google Scholar]
Morse J, Barst R, Horn E, et al. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor two mutations. J Rheumatol. 2002;29:2379–2381. [PubMed] [Google Scholar]
Liakouli V, Manetti M, Pacini A, et al. The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. Ann Rheum Dis. 2009;68:584–590. doi: 10.1136/ard.2008.088989. [DOI] [PubMed] [Google Scholar]
Pignone A, Scaletti C, Matucci-Cerinic M, et al. Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveoli-capillary impairment. Clin Exp Rheumatol. 1998;16:527–532. [PubMed] [Google Scholar]
Chizzolini C, Raschi E, Rezzonico R, et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum. 2002;46:1602–1613. doi: 10.1002/art.10361. [DOI] [PubMed] [Google Scholar]
Sgonc R, Gruschwitz MS, Boeck G, et al. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum. 2000;43:2550–2562. doi: 10.1002/1529-0131 (200011)43:11<2550::AID-ANR24>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
